Date | Analyst | Company | Last | Target | Call | Valuation |
06/07/21 | UOB Kay Hian | Yangzijiang | 1.47 | 1.76 | Buy | |
06/15/21 | DBS Vickers | Yangzijiang | 1.4 | 1.8 | Buy | |
06/25/21 | CIMB | Yangzijiang | 1.39 | 1.63 | Add | PB1x |
07/01/21 | UOB Kay Hian | Yangzijiang | 1.41 | 1.9 | Buy | PER9.3x, PB1x FY22 |
07/22/21 | Citi Research | Yangzijiang | 1.36 | 1.8 | Buy | |
07/22/21 | Lim & Tan | Yangzijiang | 1.36 | 1.64 | Accumulate | |
08/02/21 | CIMB | Yangzijiang | 1.37 | 1.91 | Add | Sum of parts |
08/02/21 | DBS Vickers | Yangzijiang | 1.37 | 1.8 | Buy | Sum of parts, PER10x FY21 |
08/10/21 | UOB Kay Hian | Yangzijiang | 1.5 | 2 | Buy | |
08/12/21 | DBS Vickers | Yangzijiang | 1.49 | 1.95 | Buy | Sum of parts |
08/12/21 | OCBC | Yangzijiang | 1.49 | 1.63 | Hold | |
09/03/21 | DBS Vickers | Yangzijiang | 1.66 | 1.95 | Buy | |
09/06/21 | CIMB | Yangzijiang | 1.62 | 1.91 | Add | Sum of parts |
09/20/21 | UOB Kay Hian | Yangzijiang | 1.48 | 2 | Buy | PER |
10/01/21 | DBS Vickers | Yangzijiang | 1.38 | 1.95 | Buy | |
11/02/21 | CIMB | Yangzijiang | 1.4 | 1.91 | Add | Sum of parts |
11/02/21 | DBS Vickers | Yangzijiang | 1.4 | 1.95 | Buy | |
11/30/21 | UOB Kay Hian | Yangzijiang | 1.3 | 2 | Buy | |
12/02/21 | Citi Research | Yangzijiang | 1.29 | 1.8 | Buy | Sum of parts |
12/08/21 | DBS Vickers | Yangzijiang | 1.32 | 1.95 | Buy | |
12/10/21 | CIMB | Yangzijiang | 1.31 | 1.91 | Add | |
01/26/22 | Citi Research | Yangzijiang | 1.26 | 1.98 | Buy | |
01/26/22 | DBS Vickers | Yangzijiang | 1.26 | 1.95 | Buy | |
01/26/22 | UOB Kay Hian | Yangzijiang | 1.26 | 2 | Buy | |
02/28/22 | DBS Vickers | Yangzijiang | 1.4 | 1.95 | Buy | |
03/01/22 | DBS Vickers | Yangzijiang | 1.38 | 2.15 | Buy | Sum of parts |
03/01/22 | UOB Kay Hian | Yangzijiang | 1.38 | 1.95 | Buy | PER9.3x FY22 |
03/28/22 | Citi Research | Yangzijiang | 1.46 | 1.98 | Buy | |
03/28/22 | Lim & Tan | Yangzijiang | 1.46 | 1.73 | Buy | |
04/01/22 | DBS Vickers | Yangzijiang | 1.53 | 2.15 | Buy | Sum of parts |
04/04/22 | Lim & Tan | Yangzijiang | 1.54 | 1.75 | Buy | |
04/05/22 | CIMB | Yangzijiang | 1.56 | 2.41 | Add | Sum of parts |
04/06/22 | UOB Kay Hian | Yangzijiang | 1.58 | 1.95 | Buy | PER9.3x FY22 |
04/22/22 | OCBC | Yangzijiang | 1.54 | 0.95 | Buy | Ex-Entitlement |
05/20/22 | CIMB | Yangzijiang | 0.89 | 1.63 | Add | |
06/29/22 | UOB Kay Hian | Yangzijiang | 0.945 | 1.16 | Buy | Sum of parts |
07/07/22 | CIMB | Yangzijiang | 0.93 | 1.63 | Add | |
08/05/22 | DBS Vickers | Yangzijiang | 0.92 | 1.38 | Buy | PB1.5x, PER12x FY22 |
08/08/22 | Lim & Tan | Yangzijiang | 0.925 | 1.3 | Accumulate | |
08/10/22 | UOB Kay Hian | Yangzijiang | 0.935 | 1.16 | Buy | Sum of parts |
08/10/22 | DBS Vickers | Yangzijiang | 0.935 | 1.4 | Buy | |
09/09/22 | DBS Vickers | Yangzijiang | 0.9 | 1.4 | Buy | |
09/09/22 | CIMB | Yangzijiang | 0.9 | 1.63 | Add | |
10/06/22 | UOB Kay Hian | Yangzijiang | 1.04 | 1.44 | Buy | PER9x FY22/23 |
10/07/22 | Lim & Tan | Yangzijiang | 1.1 | 0 | Buy | |
10/27/22 | CIMB | Yangzijiang | 1.22 | 1.63 | Add | |
11/14/22 | UOB Kay Hian | Yangzijiang | 1.38 | 1.44 | Buy | |
11/14/22 | DBS Vickers | Yangzijiang | 1.38 | 1.4 | Buy | |
11/15/22 | UOB Kay Hian | Yangzijiang | 1.39 | 1.55 | Hold | PER9x FY23 |
11/15/22 | DBS Vickers | Yangzijiang | 1.39 | 1.7 | Buy | PB1.7x FY23, PER11x FY23 |
12/02/22 | CIMB | Yangzijiang | 1.4 | 1.63 | Add |
Friday, December 2, 2022
Yangzijiang - Stock calls
Wing Tai - Stock calls
Date | Analyst | Company | Last | Target | Call | Valuation |
08/27/21 | Lim & Tan | Wing Tai | 1.83 | 2 | Accumulate | |
06/27/22 | DBS Vickers | Wing Tai | 1.76 | 2.05 | Buy | RNAV (50% disc) |
08/26/22 | Lim & Tan | Wing Tai | 1.61 | 2.05 | Accumulate | |
08/29/22 | DBS Vickers | Wing Tai | 1.68 | 2.05 | Buy | |
09/12/22 | DBS Vickers | Wing Tai | 1.66 | 2.05 | Buy | |
11/01/22 | DBS Vickers | Wing Tai | 1.52 | 2.05 | Buy | |
11/11/22 | Lim & Tan | Wing Tai | 1.47 | 1.95 | Accumulate |
Stock calls for 2 December 2022
Date | Analyst | Company | Last | Target | Call | Valuation |
12/02/22 | UOB Kay Hian | BRC Asia | 1.82 | 2.42 | Buy | PER7x FY23 |
12/02/22 | DBS Vickers | BRC Asia | 1.82 | 2.22 | Buy | PER8.2x FY23 |
12/02/22 | CIMB | BRC Asia | 1.82 | 2.5 | Add | |
12/02/22 | DMG & Partners | City Developments | 8.31 | 9.75 | Buy | RNAV (45% disc) |
12/02/22 | Lim & Tan | Civmec | 0.585 | 0 | Buy | |
12/02/22 | Lim & Tan | Ireit | 0.53 | 0.69 | Accumulate | DDM |
12/02/22 | CIMB | Yangzijiang | 1.4 | 1.63 | Add |
The latest study showed that omicron's pathogenicity was more lethal for elderly and infants.
The so-called "mildness" of omicron had been debunked by the latest study. The vulnerable groups (infants and elderly) had depicted the true severity of omicron because they're the least to be affected by exogenous factors (vaccines & covid drugs) that would skew the data. Although the elderly group is usually the first group to be vaccinated, most of them have pre-existing medical conditions that make them vulnerable. The infant group is the most suitable segment to determine the pathogenicity of covid because they're unvaccinated.
The chart above showed that BA1 was the most lethal variant for infants and elderly and BA2 and BA5 were more lethal than delta for the same groups.